Original news and analysis on international IP policy
The European Union trade secrets directive passed its final hurdle on 27 May when EU governments backed compromise text approved by the European Parliament on 14 April. Once the law has been formally published, member states will have up to two years to incorporate its provisions into domestic law.
According to a new report, by 2050, some 10 million lives could be lost a year due to antimicrobial resistance. This is an issue which has been central to this year’s World Health Assembly, and is of global consequence. Delegates gathered for the occasion noted a report by the World Health Organization secretariat on the global action plan on antimicrobial resistance adopted last year and options to develop a global stewardship framework to try to limit the use of antibiotics and develop new ones.
A side event to the World Health Assembly organised by a number of delegations on antibiotic research and innovation reflected the deep global concern about antimicrobial resistance and the lack of candidates to replace what was once considered as a miracle of modern medicine.
Public health advocates - and many nations - had high hopes that this year's World Health Assembly could finally agree on some alternative ways to fund research and development that leads to affordable medical products by de-linking R&D costs from prices, through the long-awaited discussion of a landmark 2012 report of a WHO expert group on medical R&D. This week, that discussion has spread across the highest profile topics of the week such as antimicrobial resistance and emergencies, but some are concerned that the public health safeguards recommended by the expert group may be being left behind.
Adopted five years ago, the World Health Organization Pandemic Influenza Preparedness (PIP) Framework is currently undergoing its first review. Member states gathered in committee at the World Health Assembly yesterday mostly expressed support for the framework, and took note of a report by the WHO secretariat.
At a side event to this week's World Health Assembly, GlaxoSmithKline detailed measures taken by the company to dispel the perception of conflict of interest, and build trust, including amending the ways its sales forces operate, and no longer paying speakers at scientific congresses, and said it wants to provide leadership on the issue. Patients and physicians associations call for mainstreaming those practices.
The 28 European Union member governments are preparing to request the European Commission to conduct an in-depth evaluation of the availability and affordability of EU medicinal products that could lead to changes in R&D and pricing models. An apparent first-of-its-kind, the assessment would look at market and data exclusivity, supplementary protection certificates, and intellectual property issues, according to an alleged copy of the draft Council conclusions obtained by Intellectual Property Watch.
In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Tim Wilsdon, Vice President, CRA.
At a side event to this week’s annual World Health Assembly, a member of the Netherlands Ministry of Health delivered an unexpected speech on access to medicines, calling for more clarity in the setting of medicine prices, looking inside and outside of the patent system for solutions, and praising de-linkage. Other panellists viewed partnerships as a key ingredient to fill research and development gaps. And a representative from the Gates Foundation advised against a hasty switch to new system.
A new initiative seeking to develop new antibiotic treatments is being launched today at the annual World Health Assembly. The Global Antibiotic Research and Development (GARD) is a partnership between the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi).